National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Zerbaxa® is indicated for the treatment of complicated urinary tract infections (cUTI), acute pyelonephritis and complicated intra-abdominal infections (cIAI) in adults.

 

Rapid Review

Commenced Completed Outcome
03/03/2016 26/04/2016 Full Pharmacoeconomic Evaluation recommended at the Submitted Price.

September 2016

The HSE has approved reimbursement following confidential price negotiations.